Takeda Takes GammaDelta Therapeutics
GammaDelta is researching gamma-delta T cells for use in immunotherapy, primarily addressing solid tumors. Takeda first took an equity stake and the exclusive right to buy the London-based firm in May 2017.
The deal gives Takeda access to GammaDelta’s allogeneic variable delta 1 gamma-delta T cell therapy platforms, which include both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.
“Gamma-delta T cell-based therapies represent a differentiated approach to target both solid tumors and hematological malignancies, and we are eager to integrate GammaDelta’s cell therapy platforms into our immuno-oncology R&D efforts,” said Christopher Arendt, head of Takeda’s oncology cell therapy and therapeutic area unit.
GammaDelta’s CEO Paolo Paoletti added that the companies had made “great strides in developing our proprietary gamma-deltaT cell therapy platforms, which have enabled the development of a pipeline of innovative cell therapies and allowed for the advancement of our first program into Phase 1 clinical development.”
Author: Elaine Burridge, Freelance Journalist
-
Following a multi-year collaboration, Japan’s Takeda has exercised an option to buy the UK’s GammaDelta Therapeutics, which is researching gamma-delta T cells for immunotherapy, primarily addressing solid tumors. The deal will close early in Takeda’s 2022 fiscal year. (c) Takeda
